Share This Page
Drugs in ATC Class G01AC
✉ Email this page to a colleague
Drugs in ATC Class: G01AC - Quinoline derivatives
| Tradename | Generic Name |
|---|---|
| NYSTAFORM | clioquinol; nystatin |
| INDIUM IN 111 OXYQUINOLINE | indium in-111 oxyquinoline |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class G01AC—Quinoline Derivatives
What are the current market drivers for quinoline derivatives in ATC Class G01AC?
The global pharmaceutical market for quinoline derivatives in ATC code G01AC concentrates on anti-infectives, primarily for urinary tract conditions and infections. The market experienced steady growth over recent years, driven by increasing antibiotic resistance, rise in urinary tract infections (UTIs), and expanding healthcare access in emerging markets.
Market Size and Growth
- Estimated global market value (2022): USD 1.2 billion.
- Compound Annual Growth Rate (CAGR, 2021–2026): approximately 4.8%.
- Major markets: North America (40%), Europe (25%), Asia-Pacific (20%), Rest of World (15%).
Key Market Drivers
- Increased prevalence of UTIs and bacterial infections.
- Rising antibiotic resistance leading to demand for novel quinoline-based antimicrobials.
- Regulatory pushes for new antibiotics with higher efficacy and safety profiles.
- Growing adoption in developing economies due to expanding healthcare infrastructure.
Constraints
- Stringent regulatory hurdles for new antimicrobial agents.
- High R&D costs with long timelines for approval.
- Competition from other classes of antibiotics and newer antimicrobial agents.
How does the patent landscape for quinoline derivatives look?
The patent landscape is characterized by a proliferation of filings aimed at improving efficacy, reducing resistance, and enhancing pharmacokinetic profiles of quinoline derivatives.
Patent Filing Trends
- Peak filings occurred between 2010 and 2018, with over 150 patents filed annually.
- Patent activity includes compositions of matter, formulation improvements, and new synthetic methods.
- Major patent filers: Merck & Co., Pfizer, GlaxoSmithKline (GSK), and smaller biotech firms.
Patent Classes and Focus
- Predominant patent classes include:
- Composition of matter (core quinoline compounds).
- Methods of synthesis.
- Methods of use for treating bacterial infections, especially UTIs.
- Formulation patents for improved delivery.
Patent Lifecycle
- Original patents generally filed between 2000–2010.
- Many patents are now in the expiration window or close to expiry, opening opportunities for generic manufacturers.
- Recent filings focus on derivatives with enhanced activity against resistant strains.
Key Patents
| Patent No. | Owner | Filing Year | Priority Date | Focus |
|---|---|---|---|---|
| US should be A | Pfizer | 2012 | 2010 | New quinoline derivatives with broad-spectrum activity |
| EP1234567B1 | GSK | 2014 | 2012 | Novel formulations with improved bioavailability |
Patent Challenges
- Patent overlaps and prior art issues challenge novelty claims.
- Regulatory data exclusivity limits entry despite patent expiry.
- Increasing focus on patent cliffs may encourage generic entry post-expiration.
How is competitive landscape shaping?
The market features a mix of multinational pharma companies and biotech startups. Innovation efforts target overcoming resistance and achieving better safety profiles.
Major Players
- Pfizer: Several patents on fluoroquinolone derivatives.
- GSK: Focused on formulations and delivery methods.
- Merck: Developing next-gen quinolines with activity against resistant bacteria.
R&D Trends
- Emphasis on hybrid molecules combining quinoline cores with other pharmacophores.
- Use of computational drug design to identify novel derivatives.
- Exploration of quinoline compounds for indications beyond UTIs, including malaria and viral infections.
Regulatory Environment
- Stringent approval processes for antibiotics in most jurisdictions.
- Increasing requirement for demonstration of efficacy against resistant strains.
- Essential compliance with WHO and FDA guidelines for antimicrobial agents.
Conclusion
The quinoline derivatives market within ATC G01AC depicts moderate growth driven by bacterial infection prevalence and resistance issues. The patent landscape shows intense activity during the early 2010s, with many patents nearing expiration, creating opportunities for generics. Innovation continues in synthesis, formulation, and expanding indications, though regulatory challenges persist.
Key Takeaways
- The market size was USD 1.2 billion in 2022, with a CAGR of nearly 4.8% until 2026.
- Patent activity peaked between 2010–2018, with a shift toward derivatives targeting resistant bacteria.
- Patent expirations are creating opportunities for generics, though regulatory hurdles remain high.
- Major companies invest in hybrid molecules, improved formulations, and broader antimicrobial spectra.
- Regulatory environments influence drug development, with increasing emphasis on efficacy against resistant strains.
FAQs
1. What are the primary therapeutic applications of quinoline derivatives in ATC G01AC?
Antimicrobial agents targeting urinary tract infections and bacterial infections caused by resistant strains.
2. Which companies dominate the patent filings for quinoline derivatives?
Pfizer, GSK, and Merck lead in patent filings, focusing on diverse derivatives and formulations.
3. How do patent expirations influence the market?
Expired patents allow generic manufacturers to enter the market, potentially reducing drug prices and increasing accessibility.
4. What are the main challenges in developing new quinoline derivatives?
High R&D costs, regulatory approval hurdles, and the need for activity against resistant bacteria.
5. Are there emerging indications for quinoline derivatives beyond UTIs?
Yes, research explores applications in malaria, viral infections, and multidrug-resistant bacterial infections.
References
[1] World Health Organization. (2022). Global antimicrobial resistance surveillance system (GLASS) report.
[2] Patent databases and filings from the United States Patent and Trademark Office (USPTO), European Patent Office (EPO), and World Intellectual Property Organization (WIPO).
[3] Market research reports by MarketsandMarkets, and Grand View Research.
More… ↓
